Market Herald logo

Subscribe

Be the first with the news that moves the market
  • BioVaxys Technology Corp. (BIOV) has broadened patent coverage for its viral vaccine platform
  • BioVaxys filed an  international patent application through the Patent Cooperation Treaty (“PCT”) for BVX-1021, its vaccine for SARS1 and other sarbecoviruses
  • CEO James Passin sat down with Sabrina Cuthbert to discuss the news
  • BioVaxys Technology is a clinical-stage biotechnology company that is developing viral and oncology vaccine platforms
  • BioVaxys Technology Corp. (BIOV) opened trading at C$0.11 per share.

BioVaxys Technology Corp. (BIOV) has broadened patent coverage for its viral vaccine platform.

BioVaxys filed an international patent application through the Patent Cooperation Treaty (“PCT”) for BVX-1021, it’s vaccine for SARS1 and other sarbecoviruses.

BVX-1021 is the subject of an ongoing research collaboration between The Ohio State University and BioVaxys that is evaluating the Company’s novel approach for a ‘universal vaccine’ that can treat a broad range of sarbecoviruses. 

An International PCT Application, which is a patent treaty with more than 150 member countries, makes it possible to seek patent protection for an invention simultaneously in a large number of countries by filing a single ‘international’ patent application.

CEO James Passin sat down with Sabrina Cuthbert to discuss the news.

BioVaxys Technology is a clinical-stage biopharma company. The company develops antiviral and anticancer vaccine platforms to treat SARS-CoV-2 and other viral infections, as well as ovarian cancer and other solid tumour types.

BioVaxys Technology Corp. (BIOV) opened trading at C$0.11 per share.


More From The Market Herald

" @ the Bell: Unrest over COVID sanctions drags markets lower

After a few solid trading sessions, Canada’s main stock index slid back into negative territory on Monday. Tech and industrial shares moved higher.

" Voyageur (TSXV:VM) completes SmoothX testing

Voyageur Pharmaceuticals (VM) has completed the production test batch of its SmoothX product for the computerized tomography (CT) imaging market in Canada.
Aleafia Health - CEO, Tricia Symmes

" Aleafia Health (TSX:AH) completes TSX review and enters fifth province

Aleafia Health (AH) has completed the TSX delisting review and has satisfied the Toronto Stock Exchange’s requirements for continued listing.

" Alpha Cognition (TSXV:ACOG) withdraws public offering

Alpha Cognition (ACOG) has withdrawn its previously-announced marketed public offering.